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OBJECTIVES: To evaluate utilisation of drugs involved in treatment of NSCLC, its
consumption in terms of expenditures units and number of packages prescribed in
Slovakia within 2008 -2011. METHODS: Statistical analysed data were abstracted
from State Institute for Drug Control SR, studied in accordance with financial units
(€) and number of packages prescribed every year. RESULTS: ATC L01 – antineo-
plastic agents is the one most prescribed out off all anticancer drugs (593 067
packages prescribed in 2011, 105 786 256,10 €). From L01XA platinum cytostatics –
cisplatina is the one most prescribed, with decreasing tendency in financial expen-
ditures spent (45 965 pcgs, 344 601,70 € in 2008 and 56 584 pcgs, 229 525,80 € in 2011)
compared to the least prescribed and most expensive oxiplatina. L01CD taxans –
paclitaxel and docetaxel has decreasing tendency in number of packages pre-
scribed and in financial expenditures. L01BC – the most prescribed fluorouracil has
decreasing tendency, the prescription of gemcitabin stagnates, utilization of kape-
citabin increases in number of packages and in financial units. L01XC monoclonal
antibodies – prescription of bevacizumab had increasing tendency until 2010 (13
405 pcgs, 11 339 764,50 € in 2008, 24 028 pcgs, 18 256 481,00 € in 2010 ), in 2011
prescription of cetuximab was higher than bevacizumab, and less money was
spent (cetuximab: 28 772 pcgs, 5 385 830,90€, bevacizumab: 22 661 pcgs, 17 045
495,70€). L01XE - inhibitors of protein kinase – erlotinib has increasing tendency in
number of packages prescribed and in financial expenditures (1 265 pcgs, 2 895
154,30 € in 2008, 2 071 pcgs, 3 687 581,00 € in 2011), tendency of gefitinib since 2010
when it entered the market is increasing, but it still did not overtook erlotinib (248
pcgs, 545 600,00 € in 2011). CONCLUSIONS: This study proved high economic bur-
den and continually rising amount of expenditures on antineoplastic agents, used
also in treatment of NSCLC.
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OBJECTIVES: To assess availability (patients’ access) to medicines for rare diseases
(Orphan Drugs; ODs) and to determine expenditures in the horizon of 7 years
(within years 2004 – 2010) in absolute figures and relative proportion related to
expenditures of all medicinal products in the Czech Republic (CR). METHODS: We
identified all OD registered until September 2011 by EMA. It was compared the year
of registration with the year of patients’ access to particular OD. Patients’ access to
ODs was defined as availability in official Czech distribution net. From the data-
bases of State Institute for Drug Control (SUKL), expenditures of particular OD
within all relevant years were calculated. RESULTS:Until September 2011, 49 out of
66 EMA registered ODs (74%) have been available. The mean duration of period
between registration year and year of availability in the Czech distribution net
(among already available ODs) was 2.27 years. This period was longer within past
years compared to recent years. The expenditures for ODs revealed an extreme
increase up to year 2007, while in recent years it has been more stable. In particular,
the expenditures (in million EUR) within years 2004 – 2010 were 0.2, 2.5, 12.8, 31.9,
51.2, 66.3 and 83.4, respectively. These expenditures represented 0.8%, 1.8%, 2.3%,
3.0% and 3.6% of total medicine expenditures within years 2006 – 2010 in CR. The
highest burden among all ODs have been represented by medicines for treatment
of Chronic Myeloid Leukemia and Renal Cell Carcinoma, those medicines repre-
sented 48.3% of all expenditures for ODs in 2010. CONCLUSIONS: It must be noted,
not all of available ODs are reimbursed on a standard basis, since some ODs have
conditional or exceptional (per particular patient) reimbursement. The current ex-
penditure for ODs in the CR is approximately 4% of total drugs expenditures, which
is comparable with other EU countries.
PCN135
THE ECONOMIC VALUE OF MEDICAL PROGRESS, THE CASE OF CANCER IN
FRANCE (1990-2010)
Le Pen C
Dauphine University, Paris, France
OBJECTIVES: Anti-cancer drugs are often challenged on the ground that most clin-
ical trials show modest gains in terms of overall survival associated with high
acquisition costs. But in the same time, many oncologists make the point that
progress is incremental and should be assessed dynamically on a longer period. We
collected various data over a 20 year period (1990-2010) to provide a retrospective
view of the progress that has been achieved in medical terms and the amount of
public resources that has been spent through better treatments. METHODS: We
constructed two scenarios. The first one is a reconstruction of what actually hap-
pened. On a yearly basis, we follow the patients who reported to have a cancer to
Health Insurance. We computed the incident cases, the number of deaths, the
number of surviving patients and the average and total treatment costs, from the
public payer’s perspective. The second one is a “counterfactual” scenario which
differs only by the assumption that medical progress has stopped in 1990. Efficacy
and cost of medicines are maintained equal to their 1990 values on the whole
remaining period. RESULTS: In that hypothetical scenario, the public payer spares
nearly 60 billions of current Euros over the whole period, compared to the “real
scenario”, partly because of a fewer number of patients to treat, partly because of a
lower average treatment cost. But in the same time, the number of deceased pa-
tients rises by 670,000 and the number of lost years of life by 3.2 million. This means
that retrospectively the medical progress has allowed to save one additional year of
life at a marginal cost of 18,500 €. in current value for the public payer.
CONCLUSIONS: Investing in new and innovative cancer treatments was an effec-
tive and a cost-effective use of public resources in years 1990-2010.
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OBJECTIVES: To compare expenditures on orphan drugs (OD) in Canada, Europe
(EU5  Belgium, Sweden and Netherlands) and Australia in 2009. METHODS: ODs
were selected for analysis according to the following inclusion criteria: 1) approved
by the European Medicines Agency (EMA) between 2001 and 2011, 2) retained EMA
orphan designation until December 2011, 3) remained available until December
2011, 4) received Canadian marketing authorization, and 5) received a Canadian
Health Technology Assessment (HTA) recommendation between 2006 and 2011.
Utilization and total sales was retrieved from IMS MIDAS data availability. Com-
parison across countries was carried out by deriving the cost/capita (expressed in
CAN$ 2011) and total expenditures were compared to total drug budget as reported
from the Organization for Economic Cooperation and Development (OECD) 2011
report. RESULTS: Of the 18 drugs selected, data on 8 drugs were reported only. In
2009, Canadian cost/capita was among the lowest ($0.29) in the 10 countries while
the highest were in France, Italy and Germany ($0.94; $0.70 and $0.66 respectively).
Differences were noted for oncology and non-oncology drugs, namely expendi-
tures in rare cancers remained among the lowest in Canada ($0.19) while these
expenditures were highest in France, Germany and Italy ($0.76; $0.47 and $0.47
respectively). This trend appears to follow previously reported low access of oncol-
ogy drugs in Canada vs. other developed systems (13/14 countries). France, Sweden
and Italy were associated with the highest percentage of expenditures (0.50%;
0.41% and 0.40% respectively) while the lowest were observed in the UK, The Neth-
erlands and Canada (0.22%; 0.19% and 0.14% respectively). CONCLUSIONS: Canada
was among the lowest in regards to cost/capita and percentage of OD expenditure
compared to total drug expenditures in 10 countries. This is likely explained by the
higher rate of HTA negative recommendations which impacts payer’s decision.
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OBJECTIVES: Health technology appraisal (HTA) recommendations from the UK
National Institute of Health and Clinical Excellence (NICE) are intended to standar-
dise health care throughout the NHS, and hasten the uptake of new, more effective
medicines that are cost-effective. Several studies have investigated whether NICE
guidance influences UK drug uptake as intended, mostly using sales data. However,
this approach does not reveal which indication, line of therapy, nor patient sub-
group a drug has been used to treat. This study aims to avoid these limitations by
using IMS Health’s Oncology Analyzer™ as the primary data source. Oncology
AnalyzerTM contains detailed records for a representative patient sample, allow-
ing analyses to be focussed on the particular indication and treatment criteria
specified in NICE HTAs.METHODS:HTAs for breast cancer drugs appraised by NICE
from 2005 to 2008 were analysed. For each HTA, the proportion of the eligible
patient sub-group that received the recommended (or not recommended) drugs
from Q1 2005 to Q1 2009 was determined. Changes in drug uptake in the relevant
patient populations were assessed for the UK, and were also compared to uptake in
similar European countries. RESULTS: NICE produced 6 HTAs for breast cancer,
encompassing 8 drugs, during the period assessed. In 5 out of 6 cases, the publica-
tion of an HTA was followed by the recommended change in UK drug uptake.
However, when UK uptake of drugs recommended by NICE was compared to up-
take of the same drugs in four other European countries (France, Germany, Italy
and Spain), the UK ranked at the bottom of the group. CONCLUSIONS: The NICE
HTAs assessed were mostly followed by the intended changes in drug uptake,
suggesting they were implemented, at least by some PCTs. Despite this, interna-
tional comparisons of uptake for these drugs revealed that the UK performed
poorly compared to similar European countries.
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OBJECTIVES: Cancer patients receiving chemotherapy are at risk of venous throm-
boembolism (VTE). Information on anticoagulants use in these patients is lacking.
This retrospective cohort study describes the patterns of anticoagulant use in this
population using a US claims database. METHODS: The MarketScan® databases, a
nationwide database covering 30 million patients annually, were used. Adult
cancer patients receiving chemotherapy6 months following the cancer diagnosis
between 2004-2010 were included. Patients with bleeding history before chemo-
therapy were excluded. Six cancer types were assessed: lung, colorectal, pancreas,
bladder, stomach, and ovary. Anticoagulant use 2 weeks before or after chemother-
apy initiation was determined using National Drug Code or Healthcare Common
Procedure Coding Systems. Anticoagulant therapy duration was calculated as the
sum of total injections administered and total days of supply from prescriptions
dispensed within 2-weeks before/after chemotherapy initiation. RESULTS:Overall,
30% (N21,101) of the total patients (N70,822) used anticoagulants within 2 weeks
before/after chemotherapy. Of these, 34% used anticoagulants 2 weeks before only,
30% 2 weeks after only, and 36% in both periods. Users’ median age was 61 years
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and 49% were male. Users with a VTE history (12%) had a longer duration of anti-
coagulant use versus those without a VTE history. Of those with a VTE history,
15% used anticoagulants for2 months. The average/median duration of therapy
was 15/2, 2.3/2, 19/12, 41/30 days for all users, users of unfractionated heparin
(UFH), low-molecular-weight heparin (LMWH), and vitamin K antagonist (VKA),
respectively. Anticoagulant use was highest in colorectal cancer patients (40%) and
lowest in bladder cancer patients (9%). Most commonly prescribed anticoagulants
were UFH (75%), VKA (20%), and LMWH (8%). CONCLUSIONS: Approximately 1/3 of
cancer patients used anticoagulants around chemotherapy. Anticoagulant use var-
ies by tumor type ranging between 9%-40%. Heparin was the most commonly
prescribed agent and VKA had the longest therapy duration.
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OBJECTIVES: To compare the potential cost of long-acting treatments with lan-
reotide vs octreotide for GEP-NET using patient treatment characteristics from the
PHARMO Record Linkage System (RLS) in the Netherlands. METHODS: A cost min-
imization model was used to compare lifetime costs of the SSAs. Data for patients
receiving outpatient dispensing of long-acting SSA (2003–2010) were selected from
PHARMO RLS. GEP-NET patients were identified by relevant hospital discharge
diagnoses. Dosing and injection intervals were assessed during the first stable
treatment period (i.e., the period of SSA dispensings with constant dosage and little
variation in injection intervals). RESULTS: A total of 82 octreotide LAR users and 10
lanreotide Autogel users were identified. Stable treatment was observed in 54/82
(66%) octreotide and 8/10 (80%) lanreotide users; median (IQR) duration of the first
stable phase was 3 (2-6) and 5 (4-6) months, respectively. Among stable users, most
received medium doses (5/8 (63%) vs 35/54 (65%)). One (2%) octreotide user and
none of the lanreotide users received low dose. High doses were received by 18/54
(33%) on octreotide vs 3/8 (38%) on lanreotide. Stratified by week, 9/54 (17%) oc-
treotide users received injections every 3 weeks or more frequently, 36/54 (67%)
every 4 weeks, 7/54 (13%) every 5 weeks and 2/54 (3%) every 6 weeks or less fre-
quently; 7/8 (88%) lanreotide users received injections every 4 weeks and 1/54 (13%)
every 6 weeks or less frequently. Mean injection intervals were 278 days for
octreotide and 3110 days for lanreotide. This resulted in an average GEP-NET
patient cost 7% less with lanreotide than octreotide based on the cost minimization
model. CONCLUSIONS: This analysis suggests long-acting lanreotide use may re-
duce costs compared with long-acting octreotide. The driver of cost savings was
the longer injection interval with lanreotide during stable treatment for GEP-NET.
The nature of the disease implies low patient numbers.
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There is limited data available on health care resource utilization (HRU) associated
with metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVES: To as-
sess HRU in mCRPC patients during treatment. METHODS: Observational, retro-
spective, year-long study conducted in 47 centres specialised in prostate cancer
(PC) in 6 countries: Belgium, France, Germany, Sweden, the Netherlands, and the
UK. Patients with confirmed mCRPC diagnosis and documented disease progres-
sion were eligible. HRU data over the previous 2 years (or from mCRPC diagnosis
onwards if 2 years) were collected from patients’ medical records by physicians.
Interim results on 212 patients, of 699 included patients, are presented below.
RESULTS: Mean age was 73.0 years. Mean time since PC diagnosis was 6.6 years. At
diagnosis, 35.7% of patients had metastases and 79.7% had Gleason score 7. At
inclusion, 33.8% of patients had never been treated with any prior chemotherapy,
35.3% had been treated with chemotherapy previously and 30.8% were currently
undergoing chemotherapy. Mean time since failure on androgen-deprivation ther-
apy was respectively 1.2, 1.6 and 1.5 years. Chemotherapy consisted principally of
docetaxel (82.0%). Patients without prior chemotherapy presented lower rates of PC
surgery (5.9%) than patients with past (11.3%) or ongoing chemotherapy (12.9%).
Palliative radiotherapy was more frequent in patients with past chemotherapy
(28.2%) than in patients without prior chemotherapy (19.1%) or with ongoing che-
motherapy (14.5%). Higher hospitalisation rates were observed in patients with
past (43.7%) or ongoing chemotherapy (43.5%) than in patients without prior che-
motherapy (23.5%). Mean hospitalisation durations were roughly equivalent (re-
spectively 6.1, 6.8 and 5.7 days). Emergency room visits were more frequent in
patients with ongoing chemotherapy (14.5%) than in patients without prior che-
motherapy (7.4%) or with past chemotherapy (9.9%). CONCLUSIONS: This study
provides HRU information, which will be implemented into a cost analysis in order
to highlight the determinants of the economic burden of mCRPC patients.
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OBJECTIVES: Chemotherapy-induced FN can result in reduced chemotherapy de-
livery, unplanned hospitalizations, increased mortality risk, and substantial HCU.
Little is known about FN-related HCU among cancer patients in Dutch clinical
practice. METHODS: Data from incident adult BC and NHL-patients from 1998–
2007 were obtained from the PHARMO Record Linkage System, including phar-
macy, hospital, and lab data. Eligible patients had12 months medical history and
received chemotherapy within 6 months after cancer diagnosis. Patients develop-
ing FN within 6 months after first chemotherapy (“FN-patients”) were matched 1:2
on gender, birth-year, and chemotherapy-regimen to patients without FN (“non-
FN-patients”). HCU-data (hospitalizations, medical procedures, drug use [number
dispensed]) was tallied from entry date (date of FN or matched date for non-FN-
patients) for up to 3 months. Statistics are descriptive with crude odds ratios (OR).
RESULTS: As a result, 80/1033 (8%) BC-patients developed FN. 95/486 (20%) NHL-
patients developed FN. Eighty and 89 FN-patients were matched, respectively.
More FN-patients than non-FN-patients were hospitalized in the first month after
entry date (BC: 73% vs 14% [OR23.0; 95%CI:(8.3-63.7)]; NHL: 78% vs 33% [OR7.6;
95%CI:(3.9-15.1)]). These differences were mainly due to FN-related hospitaliza-
tions (BC: 55% vs 1%; NHL: 47% vs 4%). FN-patients also had a longer mean length of
stay per all-cause hospitalization (BC: 4.6 vs 1.9 days; NHL: 10.1 vs 3.0 days). Mean
number of total drugs dispensed in the first month was higher in FN-patients than
in non-FN-patients (BC: 5.8 vs 3.1; NHL: 8.5 vs 3.6), as was use of anti-infectious
agents (BC: 99% vs 11%; NHL: 96% vs 20%) and other non-chemotherapy drugs. More
FN-patients than non-FN-patients had medical procedures (BC: 14% vs 3%; NHL:
13% vs 8%). HCU-differences between FN-patients and non-FN-patients were
maintained after 3 months. CONCLUSIONS: HCU in BC and NHL-patients with FN
in the Netherlands is substantial. Reduction of FN may improve quality of life and
save resources.
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OBJECTIVES: There has been concern that new oncology medicines may not be
accessible to patients due to the requirement to demonstrate cost-effectiveness in
order to gain public reimbursement. In Australia, Public Summary Documents
(PSDs) reporting on the Pharmaceutical Benefits Advisory Committee’s (PBAC) de-
cision making relating to government reimbursement of medicines have been pub-
lished since July 2005. A review of PSDs reporting on oncology drugs which pre-
sented cost-effectiveness analyses was undertaken to identify the success factors
for achieving a positive recommendation. METHODS: Data related to history, clin-
ical outcomes, cost-effectiveness and recommendations for oncology drugs from
published PSDs between July 2005 and November 2011 were extracted and
reviewed. RESULTS: Eighty-one PSDs were reviewed of which 51 were first, 18
second and 12 subsequent submissions. The PBAC recommended 26 for listing on
the Australian Pharmaceutical Benefits Scheme (PBS). Of the first, second and sub-
sequent submissions, 29%, 33% and 42% received a positive recommendation re-
spectively. Of those that reported a AU$/QALY, the range was: below $15k; 0% of
instances, 15-45k; 67%, 45-75k; 33%, 75-105k; 0% and above 105k; 0%. The findings
were generally similar when AU$/LYG was reported, however one product was
approved with AU$/LYG greater than $105k under the “rule of rescue”. Of the prod-
ucts approved with AU$/QALY or LYG greater than $45k factors that were noted
included high clinical need, risk sharing agreement and further price negotiation.
CONCLUSIONS:Cost per QALY above $45k is acceptable in conjunction with factors
such as clinical need and robust evidence. Nevertheless, further price negotiation
may be required to gain reimbursement on the Australian PBS.
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OBJECTIVES: The NICE reference case requires that health-related quality of life
(HRQoL) data should be reported directly from patients, preferably using the EQ-5D
(2008 Methods guide, updating recommendations in 2004 Methods guide). The ob-
jective of this review was to evaluate the source of utility data in oncology apprais-
als conducted since the 2004 Methods guide up to the present day. METHODS:
Completed NICE appraisals of oncology drugs conducted since the 2004 methods
guide were reviewed. Data including model structure, utility data sources, and
values reported for the main health states were extracted. RESULTS: Fifty-one
completed NICE appraisals were reviewed. This included 61 separate evaluations
accounting for MTAs. 43% provided utilities based on EQ-5D data from patients
with the relevant disease for at least one of the main health states in the model.
However, there was considerable variation within this – only 34% included EQ-5D
data for all main health states, and in only 28% were utilities precisely matched to
the indication sought (same therapy line etc. . .). Only 20% included EQ-5D data
from patients actually receiving the drug being appraised. In total, 28% of submis-
sions provided data from patients on the drug under consideration (either through
EQ-5D or another measure). Although most appraisals were for advanced/meta-
static cancer, utility values reported were reasonably high - the majority of apprais-
als reported utilities for the initial health state (typically stable disease) of between
0.65 – 0.85. CONCLUSIONS: This review highlights the paucity of available utility
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